ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
6-Gingerol Regulates the Exosomal miR-148b-3p/ACSL4/Ferroptosis Axis in an in vitro Model of Diabetic Retinopathy.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic retinopathy (DR), a leading cause of blindness, is driven by redox imbalance and ferroptosis in retinal endothelial cells. While 6-Gingerol exhibits antioxidant properties, its role in modulating exosome-mediated redox signaling in DR remains unexplored. This study investigates whether 6-Gingerol protects against DR by regulating ferroptosis via the exosomal miR-148b-3p/ACSL4 axis. Methods: Human retinal microvascular endothelial cells (HRMECs) were exposed to high glucose (HG) ± 6-Gingerol. Ferroptosis was assessed via lipid ROS, intracellular iron, and key markers (GPX4, ACSL4, FTH1). Exosomal miRNAs were profiled by sequencing, with miR-148b-3p validated as a regulator of ACSL4 through luciferase assays. Functional rescue experiments confirmed pathway specificity. Results: 6-Gingerol suppressed HG-induced ferroptosis, reducing lipid ROS by 2.1-fold (P<0.01) and iron accumulation by 1.8-fold (P<0.05), while upregulating GPX4 (3.2-fold, P<0.001). Exosomal miR-148b-3p was downregulated under HG but restored by 6-Gingerol (4.5-fold, P<0.001). miR-148b-3p directly targeted ACSL4, whose knockdown mimicked 6-Gingerol's effects, whereas ACSL4 overexpression or miR-148b-3p inhibition abolished protection. Conclusions: 6-Gingerol mitigates DR progression by inhibiting ferroptosis through exosomal miR-148b-3p/ACSL4-dependent redox regulation. These findings unveil a novel crosstalk between exosomal miRNAs and iron metabolism, positioning 6-Gingerol as a potential redox-targeted therapy for DR. Nonetheless, as the data are exclusively obtained from an in vitro model, in vivo validation is essential prior to making any translational inferences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.